|
|
|
| home > white papers > Choosing the Right CMO for HPAPI Manufacturing - AMRI |
|
|
 WHITE PAPERS |
|
AMRI
|
|
Choosing the Right CMO for HPAPI Manufacturing
|
|
Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Huge boom in Korean Pharma reported at CPhI Korea
Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders
Association (KPTA) – has seen a surge in growth across domestic and
international pharma companies, as well as a sizable rise in overall
attendees. As reported earlier this year in the provisional findings of
the CPhI Pharma Index[1], Korea has seen a rapid growth in its
international reputation (seeing its ‘overall competitiveness’ rise 14%
in the last two years), which is now translating into a sizable growth
in the market and at the event.
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
SMi Presents the 4th Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)
11-13 May 2020, Copthorne Tara Hotel, London, UK
SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th – 12th May 2020.
HPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.
More info >> |
|
|
|
